ORIC Pharmaceuticals, Inc. announced positive early safety and efficacy results from its ongoing dose escalation trial of ORIC-944, combined with androgen receptor inhibitors for metastatic castration ...

ORIC Pharmaceuticals, Inc. announced encouraging early safety and efficacy results from its ongoing Phase 1b trial evaluating ORIC-944 in combination with apalutamide in patients with metastatic ...

Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated ...

Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be ORIC Pharmaceuticals (ORIC). The reason why I believe it is important to go over this biotech ...

ORIC Pharmaceuticals (NASDAQ: ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially “best-in-class” treatments. The company’s shares have not had a great year, returning ...

Oric Pharmaceuticals Inc ((ORIC)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Received ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and ...